Evidence map›Paper›PMID 33100786›Full record

ArticleJournal of pharmacy & bioallied sciences

Relationship between clinical trials and disease burden of India: A cross-sectional study.

Rimplejeet Kaur, Jaykaran Charan, Tea Reljic, Surjit Singh, Pankaj Bhardwaj, Athanasios Tsalatsanis, Ambuj Kumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacy & bioallied sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rimplejeet KaurDepartment of Pharmacology, S. N. Medical College, Jodhpur, Rajasthan, India.
Jaykaran CharanDepartment of Pharmacology, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.
Tea ReljicDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Research Methodology and Biostatistics Core, Office of Research, Tampa, Florida, USA.
Surjit SinghDepartment of Pharmacology, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.
Pankaj BhardwajDepartment of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.
Athanasios TsalatsanisDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Research Methodology and Biostatistics Core, Office of Research, Tampa, Florida, USA.
Ambuj KumarDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Research Methodology and Biostatistics Core, Office of Research, Tampa, Florida, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResearch output/efforts in a country should be reflective of the disease burden. India is a site for several national and multinational clinical trials. However, whether clinical trials performed in India reflect the disease burden is not well known.

objectivesThe aim of this study was to evaluate the relationship between disease burden and clinical trials performed in India. MATERIALS AND

methodsWe extracted data on the disease burden from the World Health Organization (WHO) website and on characteristics of clinical trials performed in India from the Clinical Trial Registry of India (CRTI). The correlation between disease burden parameters of overall mortality, disability-adjusted life years (DALYs), years lost due to disability (YLD) and years of life lost (YLL), and the frequency of clinical trials associated with a particular disease was assessed. Additional subgroup analysis according to the number of trial centers, study phase, and medicine type was also performed.

resultsOnly 18% of clinical trials addressed top 10 diseases associated with 68.3% of overall mortality, and 8% of clinical trials addressed top 10 diseases associated with 52.3% of DALYs. Similarly, 16% of clinical trials addressed top 10 diseases associated with 53.2% YLDs. Furthermore, top 10 diseases associated with 65.9% of YLLs were addressed in only 8% of ongoing clinical trials. The overall correlation between any disease burden parameters with the diseases being explored in clinical trials was poor.

conclusionThere is a mismatch between diseases for which clinical trials are happening in the India and the disease burden of India. Measures need to be taken to fulfill this gap between demand and need.

Indexed as

Clinical trialsdisabilitydisease-adjusted life yearsdisease burdenIndiamortality

Identifiers

PMID33100786
PMCPMC7574753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.